AnteoTech broadens European market exposure, securing a Spanish and Portuguese Distribution Agreement for EuGeni
AnteoTech is pleased to welcome another newly appointed distributor to the EuGeni family. Most recently, AnteoTech has appointed Vitro Master Diagnostica (Vitro) for Spain and Portugal, the sixth exclusive distributor in Europe.
Following the appointment, Vitro Master Vitro S.A. and its Portuguese subsidiary, Master-InVitro will sell and distribute the EuGeni Reader platform and SARS-CoV-2 Antigen Rapid Diagnostic Test (RDT) in Spain and Portugal and significantly strengthen AnteoTech’s footprint in Europe.
Vitro S.A. is a Spanish private corporation specialising in the development, manufacture and distribution of in-vitro diagnostic (IVD) instruments, software and reagents. The group focuses on solutions which use non-invasive techniques such as immunohistochemistry and molecular biology diagnostics, making the EuGeni platform the perfect fit.
Vitro boast more than 30 years’ of experience in the supply of IVD reagents and platforms to a large number of Spanish hospitals and reference laboratories. Master in-Vitro, the Portuguese subsidiary, has extensive expertise in importing and marketing diagnostic products and services in Portugal.
AnteoTech will work together with Vitro S.A. and Master-InVitro to fulfil all necessary regulatory registration requirements. In parallel, AnteoTech will provide sales, marketing, and technical training to both parties to ensure a streamlined go-to-market execution.
AnteoTech CEO Derek Thomson said, “I am excited to be signing a further distributor in Europe. This brings our global distributor count to nine covering 17 distribution territories. Vitro have a strong track record in the IVD space and are perfectly positioned to execute on our EuGeni Platform strategy, placing readers into clinics and laboratories across the two countries. We have been working with Vitro over the past 6 months as they trialled the EuGeni platform with their customers in Spain, and we are very pleased for them and their subsidiary to be adding the EuGeni Platform to their IVD offering. We welcome Vitro to the team and look forward to building a strong relationship with them over the coming years.”